Wedbush Reiterates Perspective Therapeutics At Outperform With $11 Price Target

Wedbush analyst David Nierengarten reiterated an Outperform rating on Perspective Therapeutics (CATX) and kept a 12-month price target of $11. The note is supportive but contains no new operational data, so the likely market impact is limited to analyst-driven sentiment.

Analysis

Wedbush analyst David Nierengarten reiterated an Outperform rating on Perspective Therapeutics (CATX) and kept a 12-month price target of $11. The note is supportive but contains no new operational data, so the likely market impact is limited to analyst-driven sentiment.